3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Classical hematology
2
Conditions
Venous Thromboembolism
2
Neoplasms
2
Venous Thrombosis
1
Pulmonary Embolism
1
Embolism
1
Interventions
Cyclophosphamide
6
fludarabine phosphate
5
Whole-Body Irradiation
5
Mycophenolic Acid
4
Tacrolimus
3
Rituximab
3
Peripheral Blood Stem Cell Transplantation
3
Cyclosporine
3
Busulfan
3
fludarabine
2
apixaban
2
Methotrexate
2
Melphalan
2
Lenalidomide
2
Etoposide
2
CT-P10
2
Biopsy
2
Azacitidine
2
venetoclax
1
thymoglobulin
1
merphos
1
ivosidenib
1
ibrutinib
1
edoxaban
1
Vorinostat
1
Vancomycin
1
Thiotepa
1
Teicoplanin
1
TAK-243
1
Surveys and Questionnaires
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
apixaban
×
Classical hematology
×
30 days
×
Clear all
NCT07493304
2026-05-29
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3
Recruiting
1,600 enrolled
NCT04618913
2026-05-26
VICTORIE
Pfizer
Active not recruiting
1 enrolled